References
[1] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC
Guidelines for the diagnosis and management of atrial fibrillation
developed in collaboration with the European Association of
Cardio-Thoracic Surgery (EACTS). Eur Heart J . 2020.
[2] Dagres N, Chao TF, Fenelon G, et al. European Heart
Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart
Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS)
expert consensus on arrhythmias and cognitive function: what is the best
practice? Heart Rhythm . 2018;15 : e37-e60.
[3] Islam MM, Poly TN, Walther BA, et al. Association Between
Atrial Fibrillation and Dementia: A Meta-Analysis. Front Aging
Neurosci . 2019;11 : 305.
[4] Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive
impairment associated with atrial fibrillation: a meta-analysis.Ann Intern Med . 2013;158 : 338-346.
[5] Diener HC, Hart RG, Koudstaal PJ, Lane DA, Lip GYH. Atrial
Fibrillation and Cognitive Function: JACC Review Topic of the Week.J Am Coll Cardiol . 2019;73 : 612-619.
[6] Silva R, Miranda CM, Liu T, Tse G, Roever L. Atrial Fibrillation
and Risk of Dementia: Epidemiology, Mechanisms, and Effect of
Anticoagulation. Front Neurosci . 2019;13 : 18.
[7] Moffitt P, Lane DA, Park H, O’Connell J, Quinn TJ.
Thromboprophylaxis in atrial fibrillation and association with cognitive
decline: systematic review. Age Ageing . 2016;45 :
767-775.
[8] Cheng W, Liu W, Li B, Li D. Relationship of Anticoagulant
Therapy With Cognitive Impairment Among Patients With Atrial
Fibrillation: A Meta-Analysis and Systematic Review. J Cardiovasc
Pharmacol . 2018;71 : 380-387.
[9] Mongkhon P, Naser AY, Fanning L, et al. Oral
anticoagulants and risk of dementia: A systematic review and
meta-analysis of observational studies and randomized controlled trials.Neurosci Biobehav Rev . 2019;96 : 1-9.
[10] Friberg L, Rosenqvist M. Less dementia with oral
anticoagulation in atrial fibrillation. Eur Heart J .
2018;39 : 453-460.
[11] Madhavan M, Hu TY, Gersh BJ, et al. Efficacy of Warfarin
Anticoagulation and Incident Dementia in a Community-Based Cohort of
Atrial Fibrillation. Mayo Clin Proc . 2018;93 : 145-154.
[12] Mavaddat N, Roalfe A, Fletcher K, et al. Warfarin versus
aspirin for prevention of cognitive decline in atrial fibrillation:
randomized controlled trial (Birmingham Atrial Fibrillation Treatment of
the Aged Study). Stroke . 2014;45 : 1381-1386.
[13] Douiri A, McKevitt C, Emmett ES, Rudd AG, Wolfe CD. Long-term
effects of secondary prevention on cognitive function in stroke
patients. Circulation . 2013;128 : 1341-1348.
[14] Joe E, Ringman JM. Cognitive symptoms of Alzheimer’s disease:
clinical management and prevention. BMJ . 2019;367 :
l6217.
[15] Mongkhon P, Fanning L, Lau WCY, et al. Oral
anticoagulant and reduced risk of dementia in patients with atrial
fibrillation: A population-based cohort study. Heart Rhythm .
2020;17 : 706-713.
[16] Field TS, Weijs B, Curcio A, et al. Incident Atrial
Fibrillation, Dementia and the Role of Anticoagulation: A
Population-Based Cohort Study. Thromb Haemost . 2019;119 :
981-991.
[17] Nah MA, Lee KS, Hwang TY. Association Between Atrial
Fibrillation and the Risk of Dementia in the Korean Elderly: A 10-Year
Nationwide Cohort Study. J Prev Med Public Health .
2020;53 : 56-63.
[18] Krawczyk M, Fridman S, Cheng Y, Fang J, Saposnik G, Sposato LA.
Atrial fibrillation diagnosed after stroke and dementia risk: cohort
study of first-ever ischaemic stroke patients aged 65 or older.Europace . 2019;21 : 1793-1801.
[19] Ding M, Fratiglioni L, Johnell K, et al. Atrial
fibrillation, antithrombotic treatment, and cognitive aging: A
population-based study. Neurology . 2018;91 : e1732-e1740.
[20] Higgins J, Thomas J, Chandler J, et al. Cochrane
Handbook for Systematic Reviews of Interventions version 6.0 (updated
July 2019). Cochrane: Cochrane, 2019.
[21] Shamseer L, Moher D, Clarke M, et al. Preferred
reporting items for systematic review and meta-analysis protocols
(PRISMA-P) 2015: elaboration and explanation. BMJ .
2015;350 : g7647.
[22] Moher D, Shamseer L, Clarke M, et al. Preferred
reporting items for systematic review and meta-analysis protocols
(PRISMA-P) 2015 statement. Syst Rev . 2015;4 : 1.
[23] Pink J, O’Brien J, Robinson L, Longson D, Guideline C.
Dementia: assessment, management and support: summary of updated NICE
guidance. BMJ . 2018;361 : k2438.
[24] Berkman ND, Lohr KN, Ansari MT, et al. Grading the
strength of a body of evidence when assessing health care interventions:
an EPC update. J Clin Epidemiol . 2015;68 : 1312-1324.
[25] Wells G, Shea B, O’Connell D, et al. The
Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised
studies in meta-analyses. Ottawa Hospital Research Institute, 2014.
[26] Zhang J, Yu KF. What’s the relative risk? A method of
correcting the odds ratio in cohort studies of common outcomes.JAMA . 1998;280 : 1690-1691.
[27] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta-analyses. BMJ . 2003;327 : 557-560.
[28] Friberg L, Andersson T, Rosenqvist M. Less dementia and stroke
in low-risk patients with atrial fibrillation taking oral
anticoagulation. Eur Heart J . 2019;40 : 2327-2335.
[29] Kim D, Yang PS, Yu HT, et al. Risk of dementia in
stroke-free patients diagnosed with atrial fibrillation: data from a
population-based cohort. Eur Heart J . 2019;40 :
2313-2323.
[30] Barber M, Tait RC, Scott J, Rumley A, Lowe GD, Stott DJ.
Dementia in subjects with atrial fibrillation: hemostatic function and
the role of anticoagulation. J Thromb Haemost . 2004;2 :
1873-1878.
[31] Marzona I, Baviera M, Vannini T, et al. Risk of dementia
and death in patients with atrial fibrillation: A competing risk
analysis of a population-based cohort. Int J Cardiol .
2016;220 : 440-444.
[32] Zhang C, Gu ZC, Shen L, et al. Non-vitamin K Antagonist
Oral Anticoagulants and Cognitive Impairment in Atrial Fibrillation:
Insights From the Meta-Analysis of Over 90,000 Patients of Randomized
Controlled Trials and Real-World Studies. Front Aging Neurosci .
2018;10 : 258.
[33] Manolis TA, Manolis AA, Apostolopoulos EJ, Melita H, Manolis
AS. Atrial Fibrillation and Cognitive Impairment: An Associated Burden
or Burden by Association? Angiology . 2020;71 : 498-519.
[34] Rivard L, Khairy P, Talajic M, et al. Blinded Randomized
Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive
Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design.Can J Cardiol . 2019;35 : 1069-1077.
Table 1. Summary of findings of the effect of oral anticoagulant therapy
on the risk of dementia